Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP998061.RAdbGHXpclRb-9MQ61m6jQJ2fp7JwRHLvLqmTQAT24QZw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP998061.RAdbGHXpclRb-9MQ61m6jQJ2fp7JwRHLvLqmTQAT24QZw130_assertion type Assertion NP998061.RAdbGHXpclRb-9MQ61m6jQJ2fp7JwRHLvLqmTQAT24QZw130_head.
- NP998061.RAdbGHXpclRb-9MQ61m6jQJ2fp7JwRHLvLqmTQAT24QZw130_assertion description "[Recently completed experimental animal studies, human biomarker data, vascular imaging studies, and genome-wide atherosclerosis studies provide the rationale for proceeding with clinical outcome trials directed at inhibition of secretory phospholipase A(2) and lipoprotein-associated phospholipase A(2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP998061.RAdbGHXpclRb-9MQ61m6jQJ2fp7JwRHLvLqmTQAT24QZw130_provenance.
- NP998061.RAdbGHXpclRb-9MQ61m6jQJ2fp7JwRHLvLqmTQAT24QZw130_assertion evidence source_evidence_literature NP998061.RAdbGHXpclRb-9MQ61m6jQJ2fp7JwRHLvLqmTQAT24QZw130_provenance.
- NP998061.RAdbGHXpclRb-9MQ61m6jQJ2fp7JwRHLvLqmTQAT24QZw130_assertion SIO_000772 22802388 NP998061.RAdbGHXpclRb-9MQ61m6jQJ2fp7JwRHLvLqmTQAT24QZw130_provenance.
- NP998061.RAdbGHXpclRb-9MQ61m6jQJ2fp7JwRHLvLqmTQAT24QZw130_assertion wasDerivedFrom befree-2016 NP998061.RAdbGHXpclRb-9MQ61m6jQJ2fp7JwRHLvLqmTQAT24QZw130_provenance.
- NP998061.RAdbGHXpclRb-9MQ61m6jQJ2fp7JwRHLvLqmTQAT24QZw130_assertion wasGeneratedBy ECO_0000203 NP998061.RAdbGHXpclRb-9MQ61m6jQJ2fp7JwRHLvLqmTQAT24QZw130_provenance.